Emerging drugs in Europe

Esther Papaseit, Magí Farré, Fabrizio Schifano, Marta Torrens

Research output: Contribution to journalReview articleResearchpeer-review

46 Citations (Scopus)


Purpose of Review: New psychoactive substances refer to emerging substances that have appeared on the market and are not under international control. NPS have been categorized in different main groups (e.g. synthetic cannabinoids, synthetic cathinones, phenethylamines, piperazines, ketamine and phencyclidine-type substances, tryptamines). This article reviews the recent literature regarding emerging trends of NPS in Europe. Recent Findings: According to the last report of the European Union Early warning system (EWS), 73 NPS were officially identified for the first time. The more frequent NPS self-reported or detected are synthetic cannabinoids and cathinones. A combination of different NPS and also mixed with other drugs, mainly cannabis and ecstasy, is usual among experienced drug users. Acute NPS toxicity includes significant psychoactive and sympathomimetic effects. Summary: This article summarizes new European epidemiological and clinical data published between January and December 2013 on NPS. In the last few years, there has been a rapid increase in the number of NPS launched on the European drugs market. The presence of some of these new substances has been detected through surveys/questionnaires, studies in drug samples and biological fluids, and case reports and NPS-induced fatalities. Copyright © 2014 Lippincott Williams & Wilkins.
Original languageEnglish
Pages (from-to)243-250
JournalCurrent Opinion in Psychiatry
Issue number4
Publication statusPublished - 1 Jan 2014


  • Bath salts
  • designer drugs
  • legal highs
  • new psychoactive substances
  • research chemicals


Dive into the research topics of 'Emerging drugs in Europe'. Together they form a unique fingerprint.

Cite this